focus -WSS

focus

author：knowledge 2025-09-27 23:52:04 - browse：8

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Gene editing the human germline: What are the risks?

hotspot

WSS

Stem cell treatment guidelines are released by FDA

A rare thyroid diagnosis led to unexpected, all

'Make People Better': The CRISPR babies story you probably don't know

'Make People Better': The CRISPR babies story you probably don't know

U.K. researchers warn about biases in medical devices, algorithms

Ethical issues complicate the benefits of medical crowdfunding

entertainment

focus

focus

23andMe had bad news about my health. I wish a person had delivered it

Ethical issues complicate the benefits of medical crowdfunding

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Gene editing the human germline: What are the risks?

Supreme Court strikes down use of affirmative action

Humana sues Biden admin over Medicare Advantage audit rule

Medicare details structure of new drug price negotiation program

Leading voice in opioid treatment defends methadone clinic system

Heart attack and stroke risk calculators need revising

UnitedHealth increases loan offers after Change Healthcare outage

leisure time

Humana sues Biden admin over Medicare Advantage audit rule

Amazon on where the company's health care bets are headed next

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Readout Newsletter: Bluebird, CVS, Contineum

Listen: Biogen's potential pivot, & Illumina's next chapter

Illumina names Agilent executive as new CEO

focus

hotspot

knowledge

explore